Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115160562 | 11516056 | 2 | F | 20160725 | 20150917 | 20160802 | EXP | US-TAKEDA-2014TUS007300 | TAKEDA | 0.00 | Y | 0.00000 | 20160802 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115160562 | 11516056 | 1 | PS | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 15 MG, QD | U | 21073 | 15 | MG | TABLET | QD | |||||
| 115160562 | 11516056 | 2 | SS | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | UNK | U | 21073 | TABLET | ||||||||
| 115160562 | 11516056 | 3 | C | FISH OIL | FISH OIL | 1 | 360 MG, UNK | U | 0 | 360 | MG | ||||||||
| 115160562 | 11516056 | 4 | C | ASPIRIN. | ASPIRIN | 1 | 81 MG, UNK | U | 0 | 81 | MG | ||||||||
| 115160562 | 11516056 | 5 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 40 MG, QD | U | 0 | 40 | MG | QD | |||||||
| 115160562 | 11516056 | 6 | C | HALOPERIDOL /00027402/ | HALOPERIDOL | 1 | 10 MG, BID | U | 0 | 10 | MG | BID | |||||||
| 115160562 | 11516056 | 7 | C | BICALUTAMIDE. | BICALUTAMIDE | 1 | 50 MG, QD | U | 0 | 50 | MG | QD | |||||||
| 115160562 | 11516056 | 8 | C | BENZTROPINE | BENZTROPINE | 1 | 10 MG, QD | U | 0 | 10 | MG | QD | |||||||
| 115160562 | 11516056 | 9 | C | SIMVASTATINE | SIMVASTATIN | 1 | 80 MG, QD | U | 0 | 80 | MG | QD | |||||||
| 115160562 | 11516056 | 10 | C | CARVEDILOL. | CARVEDILOL | 1 | 12.5 MG, BID | U | 0 | 12.5 | MG | BID | |||||||
| 115160562 | 11516056 | 11 | C | LISINOPRIL. | LISINOPRIL | 1 | 20 MG, QD | U | 0 | 20 | MG | QD | |||||||
| 115160562 | 11516056 | 12 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 25 MG, UNK | U | 0 | 25 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 115160562 | 11516056 | 1 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 115160562 | 11516056 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 115160562 | 11516056 | Bladder cancer | |
| 115160562 | 11516056 | Myocardial infarction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 115160562 | 11516056 | 1 | 1997 | 1998 | 0 | |
| 115160562 | 11516056 | 2 | 2004 | 2012 | 0 |